Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
/in Dendritic Cells, International Publications, Malignant MelanomaImmune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
/in Colorectal Cancer, Dendritic Cells, International PublicationsBlockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsDendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
/in Brain Tumors in Children, Dendritic Cells, International PublicationsPast, Current, and Future of Immunotherapies for Prostate Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate CancerThe current state of immunotherapy for gliomas: an eye toward the future
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusBreaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusLow Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination
/in Dendritic Cells, International PublicationsSequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer